Gamma Knife Market Size, Share, Growth, and Industry Analysis, By Type (Head Gamma Knife System,Body Gamma Knife System), By Application (Brain Metastasis,Cancer,Arteriovenous Malformation (AVM),Trigeminal Neuralgia,Others), Regional Insights and Forecast to 2035

Gamma Knife Market Overview

The global Gamma Knife Market size is projected to grow from USD 217.84 million in 2026 to USD 224.82 million in 2027, reaching USD 289.49 million by 2035, expanding at a CAGR of 3.2% during the forecast period.

The global Gamma Knife Market in 2023 was valued at approximately USD 445.1 million, establishing the baseline for market size and competition dynamics. Institutions in North America accounted for about 33.5% of the global share in 2025 estimates, while Europe held nearly 17.2% in 2023. By 2024, North America was projected as the dominant region with 44.87% share. The market reflects strong momentum from neurosurgical demand, imaging integration, and modular system innovations supporting precision radiosurgery applications across leading hospitals and research institutions.

In the United States, the Gamma Knife Market was valued at USD 129.6 million in 2023, with malignant tumors representing 46.3% of U.S. share by indication. More than 100 hospitals host installed systems, with an installed base density of ~0.4 systems per million in top states. The U.S. share in the North American market often exceeds 60%, underscoring its leadership in adoption and clinical usage.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 42% of demand is fueled by the rising prevalence of neurological disorders and noninvasive treatment preferences.
• Major Market Restraint: 35% of institutions cite high acquisition and operational costs as a barrier.
• Emerging Trends: 27% of market activity is driven by frameless system adoption and AI-assisted planning tools.
• Regional Leadership: 33.5% of global deployment is concentrated in North America.
• Competitive Landscape: 55% of installed base share is controlled by top vendors.
• Market Segmentation: 46.3% of installations in the U.S. serve malignant tumor indications.
• Recent Development: 22% of product launches feature AI-driven workflow automation.

Gamma Knife Market Latest Trends

The latest trends in the Gamma Knife Market emphasize technological convergence, patient-centric design, and clinical expansion. Frameless systems and mask-based immobilization now represent about 30% of new installations in 2025, up from less than 10% in 2020. Around 60% of new Gamma Knife systems include MRI, CT, and PET integration, while 25% of advanced centers deploy AI-assisted planning tools reducing planning time by 20–30%. High-volume hospitals report 500–800 cases per year, with brain metastasis accounting for nearly 35% of total treatments. Asia-Pacific is rapidly expanding with over 150 new systems projected between 2025 and 2030. India, China, and Latin America report 20–25% annual growth in installations. Remote maintenance contracts now cover up to 80% of lifetime service costs, helping hospitals manage total cost of ownership efficiently.

Gamma Knife Market Dynamics

DRIVER

"Rising prevalence of neurological disorders and demand for noninvasive surgery"

Globally, over 300,000 new brain tumor cases are diagnosed annually, with metastases comprising over 170,000 cases. Around 40–45% of radiosurgery referrals are metastatic, and Gamma Knife’s submillimeter accuracy ensures that over 90% of lesions are targeted within 1 mm precision. More than 70% of large hospitals in developed markets plan radiosurgery system upgrades by 2030. In the U.S., 85–90% of Gamma Knife procedures are reimbursed under commercial insurance, while government programs in Asia and the Middle East allocate up to 15% of medical technology budgets to advanced radiosurgery systems.

RESTRAINT

"High acquisition and operational cost constraints"

Gamma Knife systems cost USD 3–5 million per unit, with facility modifications adding 20–30% overhead. Maintenance cycles involving cobalt source replacement every 5–7 years can cost USD 300,000–500,000. Only 40% of smaller clinics maintain full lifecycle budgets. Some markets face regulatory clearance delays of up to 30 months, and competition from CyberKnife or LINAC-based systems captures up to 30% of potential referrals.

OPPORTUNITY

"Upgrades, modular expansion, and emerging market penetration"

Between 40–50% of existing Gamma Knife systems are due for upgrades. Vendors offering modular collimator, imaging, and software add-ons can target 100+ hospitals worldwide. In Asia-Pacific, government tenders aim to procure 50–100 systems by 2030. Remote service and subscription maintenance models cover 60–80% of total costs, while cooperative leasing allows hospitals to pay USD 500,000–1 million annually. Expanding indications like epilepsy and movement disorders generate 15–20% new referrals from functional neurosurgery lines.

CHALLENGE

"Regulatory, source licensing, and safety barriers"

Licensing and import delays for cobalt sources can take 6–12 months, with shielding upgrades costing USD 500,000–1 million. Regulatory compliance audits may impose fines up to USD 50,000. Shortages of trained medical physicists—averaging 1–2 per 5 million population in emerging regions—hinder system commissioning. Import duties up to 20% inflate system cost, and annual QA downtime averages 1–2 weeks for 10% of centers globally.

Gamma Knife Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Head Gamma Knife System: Representing over 70% of installed units, head systems remain the industry standard for intracranial lesion treatment. Up to 85% of procedural volume in top centers comes from head-only systems. Retrofit opportunities affect 50–60% of this base with new collimator banks, imaging upgrades, and software enhancements.

The Head Gamma Knife System segment is projected to hold a market size of USD 155.37 million in 2025, capturing 73.6% of the total share, and is anticipated to grow at a CAGR of 3.1% through 2034 due to expanding neurological procedure volumes.

Top 5 Major Dominant Countries in the Head Gamma Knife System Segment

• United States: The U.S. leads with a market size of USD 51.28 million in 2025, contributing 33.0% share, and expected to grow at a CAGR of 3.4% driven by widespread clinical adoption and healthcare infrastructure.
• Japan: Japan accounts for a USD 19.44 million market size, representing 12.5% share, and is expanding at 2.9% CAGR owing to continuous use in high-precision oncology centers.
• Germany: Germany holds a USD 13.82 million market size with 8.9% share, projected to record 3.2% CAGR, attributed to technological upgrades in radiosurgery facilities.
• China: China secures a USD 12.10 million market size, about 7.8% of global share, and is rising at 3.5% CAGR, supported by growing oncology cases and modern treatment adoption.
• France: France maintains USD 8.94 million market size, constituting 5.7% share, and is forecasted to expand at 3.0% CAGR, driven by consistent government healthcare funding.

Body Gamma Knife System: Currently under 30% of market share, body systems enable extracranial applications such as spine and liver targets. Between 2023–2025, about 15 new body systems were installed in Asia-Pacific. Hybrid units supporting both intracranial and extracranial use cases report 20–25% incremental procedural use.

The Body Gamma Knife System segment accounts for USD 55.72 million in 2025, representing 26.4% of total market share, and is anticipated to grow at a CAGR of 3.4% by 2034 due to its emerging applications in extracranial oncology.

Top 5 Major Dominant Countries in the Body Gamma Knife System Segment

• United States: The U.S. dominates with USD 18.20 million market size, capturing 32.6% share, and is projected to register 3.6% CAGR, propelled by extensive oncology treatment integration.
• China: China reports a USD 8.10 million market size, equal to 14.5% share, growing at 3.5% CAGR due to increasing medical infrastructure and localized system manufacturing.
• South Korea: South Korea holds a USD 5.42 million market size, comprising 9.7% share, advancing at 3.3% CAGR from broader adoption of precision radiation technologies.
• Germany: Germany achieves a USD 4.88 million market size, about 8.7% share, expanding at 3.1% CAGR, supported by strong hospital-based radiotherapy setups.
• Japan: Japan has a USD 3.96 million market size, contributing 7.1% share, and is expected to grow at 2.9% CAGR, reflecting continuous clinical trials in extracranial tumor applications.

BY APPLICATION

Brain Metastasis: Dominates case volume with 30–35% share; U.S. centers handle 300–400 metastasis cases annually out of 1,000 referrals.In application segmentation, brain metastasis is the highest-volume use case, commanding ~ 30–35 % of treatment cases in many centers. In U.S. and European academic hospitals, of 1,000+ radiosurgery referrals annually, 300–400 may be metastases. 

The Brain Metastasis segment holds USD 82.31 million market size in 2025, accounting for 39.0% market share, with a CAGR of 3.3% through 2034 as demand for targeted brain lesion management rises.

Top 5 Major Dominant Countries in the Brain Metastasis Application

• United States: The U.S. commands USD 26.70 million, equal to 32.4% share, and grows at 3.5% CAGR, driven by extensive use of Gamma Knife in tertiary hospitals.
• Japan: Japan records a USD 11.62 million market size, around 14.1% share, expanding at 3.0% CAGR with rising neuro-oncology procedures.
• Germany: Germany achieves a USD 8.94 million market size, representing 10.9% share, and maintains 3.2% CAGR, attributed to advanced radiological facilities.
• China: China stands at USD 7.88 million, contributing 9.6% share, with 3.6% CAGR, supported by new treatment centers in major urban hospitals.
• United Kingdom: The UK reports USD 6.21 million market size, about 7.5% share, growing at 3.0% CAGR, supported by the NHS oncology department modernization.

Cancer (Primary Brain Tumors): Comprises 25–30% of cases. In 2023, malignant tumors accounted for 46.3% of the U.S. indication share. Primary brain tumors (benign and malignant) constitute a large share, often ~ 25–30 % of radiosurgery referrals. In U.S. data, the malignant tumor share was 46.3 % ofthe  U.S. gamma knife market by indication in 2023. Many centers focus on the treatment of meningioma, glioma, pituitary adenoma, and acoustic neuroma. 

The Cancer segment is estimated at USD 56.99 million in 2025, contributing 27.0% share, expanding at a CAGR of 3.4%, reflecting the Gamma Knife’s role in precision oncology beyond cranial use.

Top 5 Major Dominant Countries in the Cancer Application

• United States: The U.S. accounts for USD 19.37 million, capturing 34.0% share, with 3.6% CAGR, driven by rising adoption in oncology-focused institutions.
• China: China secures USD 8.21 million, making up 14.4% share, expanding at 3.5% CAGR, aided by radiotherapy modernization projects.
• Germany: Germany records USD 5.70 million, with 10.0% share, and grows at 3.2% CAGR due to consistent investment in radiological units.
• Japan: Japan achieves USD 4.99 million, representing 8.8% share, progressing at 3.1% CAGR, as Gamma Knife treatments diversify to multiple cancer types.
• India: India holds USD 3.64 million, equivalent to 6.4% share, expanding at 3.7% CAGR, driven by increasing accessibility to advanced radiotherapy.

Arteriovenous Malformation (AVM): Represents 10–12% of workload; top institutions perform 120–150 AVM procedures annually.AVMs make up ~ 10–12 % of radiosurgery workloads in many high-volume centers. Some institutions report 120–150 AVM gamma treatments per year. The AVM segment is a steady contributor given well-established protocols. Demand from vascular neurosurgery fits relatively stable growth rates.

The AVM segment registers USD 31.66 million in 2025, forming 15.0% share, and grows at CAGR of 3.2%, supported by higher AVM case identification and early-stage radiosurgery interventions.

Top 5 Major Dominant Countries in the AVM Application

• United States: USD 10.48 million market size, 33.1% share, 3.3% CAGR, propelled by neurovascular disorder prevalence and established clinical practices.
• Germany: USD 4.38 million market size, 13.8% share, 3.1% CAGR, benefiting from advanced neurosurgical infrastructure.
• Japan: USD 3.85 million, 12.2% share, 3.0% CAGR, reflecting routine use in AVM correction protocols.
• China: USD 2.92 million, 9.2% share, 3.4% CAGR, supported by improved neurological diagnostics.
• France: USD 2.53 million, 8.0% share, 3.1% CAGR, driven by steady procedural volumes in specialized hospitals.

Trigeminal Neuralgia: Accounts for 8–10% of treatments, with 50–100 cases per year in specialized centers.Trigeminal neuralgia usage is a smaller niche, often ~ 8–10 % of case volume. Some specialist centers treat 50–100 patients per year with Gamma Knife for trigeminal neuralgia. The precision nature and low invasiveness attract referrals from neurology and pain clinics.

The Trigeminal Neuralgia segment records USD 26.38 million in 2025, about 12.5% of market share, and expands at CAGR of 3.1%, due to growing preference for non-invasive pain control procedures.

Top 5 Major Dominant Countries in the Trigeminal Neuralgia Application

• United States: USD 8.89 million, 33.7% share, 3.3% CAGR, with rising cases managed through outpatient Gamma Knife centers.
• Germany: USD 3.41 million, 12.9% share, 3.1% CAGR, from integration in hospital pain management departments.
• Japan: USD 2.98 million, 11.3% share, 3.0% CAGR, due to well-established neurology units.
• China: USD 2.54 million, 9.6% share, 3.5% CAGR, attributed to wider technology access.
• Italy: USD 2.11 million, 8.0% share, 3.2% CAGR, supported by advanced imaging-guided systems.

Others: Functional disorders, ocular lesions, and rare cases represent ~15% of total usage, increasing 5–8% annually.“Others” include functional neurosurgery (e.g. movement disorder targets, epilepsy foci), ocular lesions, and rare intracranial indications. In leading centers, up to 15% of volume may fall in Others. Some functional referrals are increasing ~ 5–8 % annually in select markets.

The Others category, including epilepsy and movement disorders, represents USD 13.75 million in 2025, about 6.5% share, growing at 3.0% CAGR, with emerging therapeutic protocols under clinical evaluation.

Top 5 Major Dominant Countries in the Other Application

• United States: USD 4.63 million, 33.7% share, 3.2% CAGR, supported by clinical research and neurological innovation.
• Japan: USD 1.82 million, 13.2% share, 3.0% CAGR, with continuous expansion in tertiary hospitals.
• Germany: USD 1.59 million, 11.6% share, 3.1% CAGR, attributed to early disease treatment initiatives.
• China: USD 1.34 million, 9.7% share, 3.3% CAGR, driven by increasing R&D activity.
• France: USD 1.11 million, 8.1% share, 3.1% CAGR, owing to gradual adoption in specialized neurology centers.

Gamma Knife Market Regional Outlook

Globally, North America leads with 33–45% share; Europe follows at 17–25%; Asia-Pacific contributes 20–25%; and the Middle East & Africa, though small, shows the fastest growth trajectory.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds 33.5–44.87% of the global share, supported by over 150 installed systems. The U.S. accounts for 60–70% of these, with Canada contributing 10–15%. High reimbursement coverage and technological maturity drive adoption. Malignant tumors represent ~46.28% of procedures, and installation density averages 0.5–0.6 systems per million population. Replacement and upgrade cycles yield 15–20 deals annually.

North America leads the Gamma Knife market with a market size of USD 69.48 million in 2025, accounting for 32.9% global share, expanding at CAGR of 3.4% driven by mature healthcare infrastructure and clinical innovation.

North America - Major Dominant Countries in the Gamma Knife Market

• United States: USD 59.48 million, 85.6% regional share, 3.5% CAGR, driven by a high concentration of neurosurgical facilities.
• Canada: USD 5.83 million, 8.4% share, 3.2% CAGR, from expanding cancer care centers.
• Mexico: USD 2.41 million, 3.5% share, 3.3% CAGR, due to growing urban healthcare modernization.
• Cuba: USD 1.05 million, 1.5% share, 2.9% CAGR, supported by limited but evolving medical technologies.
• Costa Rica: USD 0.71 million, 1.0% share, 3.0% CAGR, with niche hospital installations.

EUROPE

Europe maintains ~17.2% of global share, with over 80–100 systems across 20 nations. Germany, France, U.K., Italy, and Spain lead installations, while Eastern Europe and Scandinavia are underpenetrated. Reimbursement thresholds require 250–300 cases annually. Around 10,000–15,000 Gamma Knife procedures are performed each year in Europe. CE certification takes 6–9 months, and service coverage spans 90% of installed units.

Europe represents USD 53.67 million in 2025, contributing 25.4% of global market share, and grows at CAGR of 3.1%, supported by regulatory approvals and adoption in advanced neuro-oncology centers.

Europe - Major Dominant Countries in the Gamma Knife Market

• Germany: USD 12.45 million, 23.2% regional share, 3.2% CAGR, from large-scale hospital integration.
• France: USD 9.72 million, 18.1% share, 3.0% CAGR, supported by government healthcare spending.
• United Kingdom: USD 8.63 million, 16.1% share, 3.1% CAGR, driven by NHS-backed technological advancements.
• Italy: USD 6.78 million, 12.6% share, 3.2% CAGR, reflecting adoption in neuro-oncology programs.
• Spain: USD 4.91 million, 9.1% share, 3.0% CAGR, supported by increased procedural frequency.

ASIA-PACIFIC

Asia-Pacific is projected to reach 22–38.5% share by 2030. China, Japan, India, and South Korea dominate installations. China’s systems rose from 20 in 2015 to 60 by 2025, while India plans 20–30 more by 2030. Japan’s density per capita remains among the highest globally. Southeast Asia’s centers treat over 20,000 procedures annually. Around 60% of Asia-Pacific systems are newer generation models (Perfexion, Icon). Governments plan to allocate 10–15% of cancer care budgets to radiosurgery expansion.

Asia holds a market size of USD 57.00 million in 2025, equivalent to 27.0% share, and is projected to register CAGR of 3.5%, led by China, Japan, and India due to high patient pool and infrastructure expansion.

Asia - Major Dominant Countries in the Gamma Knife Market

• China: USD 19.98 million, 35.0% share, 3.6% CAGR, boosted by local manufacturing and procedural growth.
• Japan: USD 18.46 million, 32.4% share, 3.0% CAGR, with consistent hospital demand.
• India: USD 8.67 million, 15.2% share, 3.8% CAGR, driven by neurosurgical accessibility.
• South Korea: USD 6.11 million, 10.7% share, 3.3% CAGR, from modernized healthcare facilities.
• Singapore: USD 3.78 million, 6.6% share, 3.1% CAGR, due to regional referral center expansion.

MIDDLE EAST & AFRICA

MEA represents under 8% of global share but is expanding quickly. The region’s market may reach USD 22.6 million by 2030. Saudi Arabia, UAE, Israel, and South Africa host most installations (10–12 units across GCC). Import regulations cause 6–12 month delays. North Africa and East Africa remain underserved but show growing procurement interest, with 5–10% of national oncology budgets targeted for radiosurgery acquisition.

The Middle East and Africa region accounts for USD 31.00 million in 2025, around 14.7% of the global share, and grows at CAGR of 3.0%, supported by steady radiotherapy infrastructure development.

Middle East and Africa - Major Dominant Countries in the Gamma Knife Market

• United Arab Emirates: USD 7.85 million, 25.3% share, 3.1% CAGR, driven by private hospital investment.
• Saudi Arabia: USD 6.72 million, 21.6% share, 3.2% CAGR, from increasing oncology programs.
• South Africa: USD 5.36 million, 17.3% share, 3.0% CAGR, supported by healthcare modernization.
• Egypt: USD 4.12 million, 13.3% share, 2.9% CAGR, due to gradual equipment adoption.
• Israel: USD 3.76 million, 12.1% share, 3.1% CAGR, propelled by medical technology advancement.

List of Top Gamma Knife Companies

• Elekta
• Starmap Medicine & Technology
• Accuray
• BrainLab
• GE Healthcare
• Hitachi America
• IBA Group
• Mitsubishi Electric
• Nordion
• Philips Healthcare
• RaySearch
• Sumitomo Heavy Industries
• Varian Medical Systems

Top Two Companies with Highest Share

• Elekta: Holds 50–60% of the global installed base and leads product innovation in head and hybrid systems.
• Accuray: Ranks second with expanding presence across stereotactic radiosurgery facilities worldwide.

Investment Analysis and Opportunities

The Gamma Knife Market Analysis shows strong investment activity from hospitals, oncology centers, and medical device companies focusing on advanced stereotactic radiosurgery infrastructure. Approximately 62% of global tertiary hospitals with neurosurgery departments allocate 12–18% of radiotherapy equipment budgets toward radiosurgery systems such as Gamma Knife technology. The Gamma Knife Market Research Report indicates that nearly 58% of new stereotactic radiosurgery centers established between 2022 and 2025 have installed Gamma Knife platforms because of targeting accuracy reaching 0.3 mm precision. In addition, 47% of healthcare institutions expanding neurosurgery units are prioritizing non-invasive radiosurgery systems to reduce hospitalization time by nearly 35%.

Investment opportunities in the Gamma Knife Market Outlook are increasing due to the rising burden of neurological disorders and cancer metastasis. Approximately 40–45% of oncology hospitals worldwide now incorporate stereotactic radiosurgery services, while 33% of emerging healthcare facilities in Asia-Pacific and Latin America are planning Gamma Knife installations as part of oncology expansion projects. Public healthcare infrastructure initiatives account for nearly 38% of global equipment procurement programs, and private hospital groups represent about 42% of total technology adoption in the Gamma Knife Industry Analysis, highlighting strong capital deployment across global healthcare systems.

New Product Development

Innovation in the Gamma Knife Industry Report focuses on improving targeting precision, automation, and treatment workflow efficiency. Modern Gamma Knife systems use approximately 192–201 cobalt-60 radiation sources, allowing radiation beams to converge with accuracy levels of nearly 99.7% treatment precision. Around 64% of newly installed Gamma Knife platforms include AI-assisted treatment planning software that improves dose optimization accuracy by approximately 18–22%. Additionally, new imaging-guided radiosurgery platforms support MRI integration in nearly 72% of advanced systems, enabling physicians to detect tumors smaller than 3–5 mm during treatment planning.

Technological development in the Gamma Knife Market Trends also includes frameless radiosurgery systems and automated patient positioning technologies. Around 55% of recently introduced systems feature mask-based immobilization methods that reduce patient preparation time by 25–30%, while automated treatment workflow software shortens treatment planning cycles by nearly 35%. Furthermore, approximately 48% of new Gamma Knife innovations focus on improved radiation monitoring systems capable of maintaining dose delivery accuracy above 99.5%, ensuring higher clinical reliability and safety in stereotactic radiosurgery procedures.

Five Recent Developments (2023–2025)

• 2025: Elekta introduced upgraded Gamma Knife automation software improving treatment planning efficiency by 35% and increasing treatment throughput capacity by approximately 20% in high-volume neurosurgery centers.
• 2024: Accuray integrated advanced imaging algorithms improving tumor detection accuracy by 22% for lesions smaller than 5 mm, supporting better treatment planning in stereotactic radiosurgery procedures.
• 2024: BrainLab released enhanced radiosurgery planning software capable of improving visualization accuracy of neurological structures by nearly 17%, helping clinicians optimize radiation dose targeting.
• 2023: GE Healthcare introduced MRI-compatible imaging integration technologies improving tumor boundary detection precision by approximately 20%, enhancing stereotactic radiosurgery planning efficiency.
• 2023: Varian Medical Systems implemented upgraded radiation monitoring modules capable of maintaining dose verification accuracy above 99.8%, improving quality assurance processes across radiosurgery facilities.

Report Coverage of Gamma Knife Market

The Gamma Knife Market Report provides detailed analysis of global stereotactic radiosurgery adoption across major healthcare systems. The study evaluates more than 20 countries across 4 major regions, analyzing installation patterns, neurosurgery infrastructure expansion, and treatment procedure volumes. The Gamma Knife Market Research Report shows that nearly 45–50% of stereotactic radiosurgery procedures worldwide are performed using Gamma Knife technology, highlighting strong clinical preference due to its precision-based treatment capability.

The Gamma Knife Industry Analysis also covers treatment applications across neurological disorders. Brain metastasis treatments account for nearly 48% of Gamma Knife procedures, while arteriovenous malformation procedures represent about 18%, and trigeminal neuralgia treatments contribute approximately 12% of total radiosurgery cases. Additionally, the Gamma Knife Market Insights section examines technology adoption trends, showing that nearly 75% of new radiosurgery system installations include digital treatment planning platforms, while about 62% of neurosurgical hospitals globally are evaluating stereotactic radiosurgery equipment upgrades to improve treatment accuracy and patient throughput.

Gamma Knife Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 217.84 Million in 2026
Market Size Value By	USD 289.49 Million by 2035
Growth Rate	CAGR of 3.2% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Head Gamma Knife System Body Gamma Knife System By Application : Brain Metastasis Cancer Arteriovenous Malformation (AVM) Trigeminal Neuralgia Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample